IBA - Transparency notification
Louvain-la-Neuve, Belgium, January 13, 2017, 7.00 a.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification , in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings.
The Press Release dated December 15, 2016 regarding Capfi Delen Asset Management NV has to be disregarded. Indeed, notwithstanding December 15, 2016's capital increase, Capfi Delen Asset Management NV has not passively crossed downwards the 3% threshold.
* * *
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com .
For more information, please contact
Corporate Legal Counsel
+32 10 201 159
Last updated on: 15/01/2017
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.